Group 1 - The company expects a net profit attributable to shareholders of the parent company for the first half of 2025 to be between 46 million to 52 million yuan, representing an increase of 27.06 million to 33.06 million yuan compared to the same period last year, which is a year-on-year increase of 142.84% to 174.52% [1] - The net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, is expected to increase by 55.80% to 86.33% [2] - The increase in profit is primarily due to an increase in operating income and an improvement in gross profit margin during the reporting period [2] Group 2 - The net profit for the same period last year was 18.94 million yuan, and the net profit after deducting non-recurring gains and losses was 19.66 million yuan [2] - The earnings per share for the same period last year was 0.09 yuan [2] - The performance forecast data is preliminary and subject to final disclosure by the company [2]
美诺华: 宁波美诺华药业股份有限公司2025年半年度业绩预增公告